Amer Zeidan, MBBS, MHS is an Assistant Professor of Medicine (Hematology) at Yale University since July 2014. Dr. Zeidan completed a hematology/oncology fellowship and a clinical research fellowship in myelodysplastic syndromes (MDS) at Johns Hopkins University where he also earned a Master of Health Science (MHS) degree in Clinical Investigation. He received his MBBS degree…
Amer Zeidan, MBBS, MHS is an Assistant Professor of Medicine (Hematology) at Yale University since July 2014. Dr. Zeidan completed a hematology/oncology fellowship and a clinical research fellowship in myelodysplastic syndromes (MDS) at Johns Hopkins University where he also earned a Master of Health Science (MHS) degree in Clinical Investigation. He received his MBBS degree from the Faculty of Medicine, University of Jordan, Amman, Jordan before completing his internal medicine residency at Rochester General Hospital, Rochester, NY. Dr. Zeidan specializes in the management of MDS and acute myeloid leukemia (AML). He is a nationally and internationally recognized expert in the clinical management of myeloid malignancies. The focus of Dr. Zeidan’s clinical/translational research is the development of novel therapies for MDS, AML, and other myeloid malignancies. Dr. Zeidan is the principal investigator on several investigator-initiated, cooperative group and industry-sponsored clinical trials in MDS, AML and other hematologic malignancies. Dr. Zeidan especially focuses on the use of immunotherapy especially combination-based approaches for myeloid malignancies.
The second area of research interest for Dr. Zeidan is effectiveness and outcomes research in hematologic malignancies; a type of research that evaluates how much benefit do patients achieve from existing treatments at the real-world community level in comparison to what is seen in the controlled clinical trials setting. This research aims to identify barriers and ultimately study strategies that could improve the outcomes of patients with myeloid malignancies at the population level. Dr. Zeidan conducts this research with collaborators within the Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center at Yale University.
Dr. Zeidan has been awarded the American Society of Clinical Oncology Young Investigator Award (ASCO YIA), the Aplastic Anemia and MDS International Foundation (AAMDSIF)/Ed Evan’s Foundation- MDS Clinical Research Consortium Fellowship award, The Tito Bastianello Young Investigator Award and multiple abstract achievements and travel awards. Dr. Zeidan has most recently received the Leukemia and Lymphoma Society Scholar in Clinical Research and the National Cancer Institute Cancer Clinical Investigator Team Leadership awards. Dr. Zeidan has presented his research in multiple national and international meetings and has been an invited speaker nationally and internationally including Mexico, Bulgaria, Spain, Sri Lanka, Indonesia, South Korea, Jordan and others. He was the lead presenter of MDS review at the American Society of Hematology (ASH) Annual Meeting 2018 highlights meetings in USA and Asia-Pacific. Dr. Zeidan in a member of the Northern American National Cooperative groups’ MDS Working Group which is working to implement precision medicine to develop MDS master clinical protocols for North America. Dr. Zeidan is also a member of the MDS Foundation International Working Group-PM working to improve prognostic and predictive assessments in MDS. Dr. Zeidan has served on the National Comprehensive Cancer Center Network (NCCN) clinical guidelines for MDS panel. He is an author on more than 140 peer-reviewed publications and book chapters. Dr. Zeidan also serves on the editorial board of important hematology journals such as Blood Reviews and Leukemia and Lymphoma journals and has been an ad hoc reviewer for many prestigious journals including New England Journal of Medicine, Lancet Oncology, Blood, Journal of Clinical Oncology JAMA Oncology and others.